Abstract
Solitary fibrous tumor (SFT) is a spectrum of mesenchymal tumors characterized by a branching (staghorn-like) vascular pattern and the specific NAB2 :: STAT6 gene fusion. Myxoid SFT is a rare histological variant defined by myxoid stroma constituting over 50% of the tumor volume. Although most myxoid SFTs exhibit benign or indolent behavior, recent reports have demonstrated that this variant can also exhibit aggressive biological behavior. To our knowledge, malignant myxoid SFT arising in the retroperitoneum with integrative clinicopathological and molecular characterization has been rarely documented. We report a case of malignant myxoid SFT arising in the retroperitoneum and discuss its clinicopathological features with a literature review. A woman in her mid-50s presented with lower abdominal pain for over one month. Imaging revealed a pelvic mass that was initially clinically diagnosed as a uterine leiomyoma. Intraoperative exploration identified the mass in the retroperitoneum, and complete resection was performed. Gross examination showed a tumor measuring 11 cm in greatest dimension with a gray-white to gray-red, soft cut surface, predominantly gelatinous in appearance. Histopathological examination revealed a spindle cell tumor with prominent myxoid stroma (approximately 60% of the tumor volume), a mitotic count of approximately 10/10 high-power fields (HPF; equivalent to 5/mm 2 ), and coagulative tumor necrosis (approximately 15%). Immunohistochemistry demonstrated diffuse strong positivity for CD34 and STAT6, weak positivity for Bcl-2, and focal weak positivity for CDK4 and MDM2. DNA-based next-generation sequencing (NGS) detected an NAB2 :: STAT6 fusion gene and no MDM2 amplification, confirming the diagnosis of myxoid malignant SFT. According to the modified Demicco risk stratification model (age ≥55 years, tumor size 11 cm, mitotic count ≥4/10 HPF, necrosis ≥10%), the case scored 6 points, placing it in the high-risk category. The patient received adjuvant radiotherapy (45 Gy in 25 fractions to the PCTV) and remained disease-free without evidence of recurrence or metastasis throughout the 17-month follow-up period. Malignant myxoid SFT arising in the retroperitoneum is extremely rare and poses significant diagnostic challenges. Accurate diagnosis can be supported by histopathological and immunohistochemical examinations (including CD34, STAT6, and BCL2), and molecular detection of the NAB2 :: STAT6 fusion gene can serve as a valuable adjunct, especially in cases where morphological and immunohistochemical findings are atypical or when differential diagnosis is challenging. Complete surgical resection is the cornerstone of treatment. Adjuvant therapy and close long-term surveillance should be considered for patients with high-risk features. To the best of our knowledge, this case supplements the clinicopathological data of this rare entity occurring in the retroperitoneum with overt malignant biological behavior, and further case reports and studies are essential to refine the diagnostic criteria and optimize treatment strategies for this tumor.

This publication has 34 references indexed in Scilit: